Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report

Sickle cell disease is an autosomal recessive disorder characterized by the presence of sickle hemoglobin that leads to chronic hemolysis and vaso-occlusive crisis. After decades of limited therapy options, crizanlizumab is a humanized monoclonal antibody approved by the Food and Drug Administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshurafa, Awni, Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745667/
https://www.ncbi.nlm.nih.gov/pubmed/36523780
http://dx.doi.org/10.3389/fmed.2022.1048571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745667/
https://www.ncbi.nlm.nih.gov/pubmed/36523780
http://dx.doi.org/10.3389/fmed.2022.1048571

Ejemplares similares